Literature DB >> 6466196

No effect of nifedipine on atherogenesis in cholesterol-fed rabbits.

S Stender, I Stender, B Nordestgaard, K Kjeldsen.   

Abstract

It was recently reported that the calcium antagonist nifedipine suppresses aortic cholesterol accumulation in cholesterol-fed rabbits without reducing hypercholesterolemia. We extended this study on plasma lipoprotein levels and aortic influx of cholesteryl ester. We gave 40 mg per day of nifedipine orally to 17 rabbits fed a 2% cholesterol diet for 8 weeks. For the same period of time 15 control rabbits received placebo capsules and the same diet. During the study, total cholesterol, HDL, LDL, and VLDL cholesterol concentrations in plasma were not significantly different in the experimental and control animals. At the end of the study we found no difference in the two groups in accumulation of cholesterol in the intima media of the proximal thoracic aorta, the distal thoracic aorta, and the corresponding media layers. Furthermore, aortic influx of free cholesterol, cholesteryl ester, and albumin from plasma measured by radioactive tracers was not significantly affected by nifedipine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6466196     DOI: 10.1161/01.atv.4.4.389

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  12 in total

Review 1.  Atherosclerosis: inhibition of regression as therapeutic possibilities.

Authors:  M J Davies; D M Krikler; D Katz
Journal:  Br Heart J       Date:  1991-06

2.  Quantitative analysis of antiatherosclerotic effect of nifedipine in cholesterol-fed rabbits.

Authors:  Y Ohta; N Higuchi; S Emura; T Takashima; K Oogushi; H Kato; K Ohmori; T Sunaga
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Effect of nifedipine administration on pulse wave velocity (PWV) of chronic hemodialysis patients--2-year trial.

Authors:  Y Saito; K Shirai; J Uchino; M Okazawa; Y Hattori; T Yoshida; S Yoshida
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

4.  Retardation of development and progression of coronary atherosclerosis: a new indication for calcium antagonists?

Authors:  W Schneider; G Kober; P Roebruck; H Noack; M Alle; G Cieslinski; N Reifart; M Kaltenbach
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Suppression of rat carotid lesion development by the calcium channel blocker PN 200-110.

Authors:  D A Handley; R G Van Valen; M K Melden; R N Saunders
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

Review 6.  Modification of atherosclerosis by agents that do not lower cholesterol.

Authors:  J G Cleland; D M Krikler
Journal:  Br Heart J       Date:  1993-01

7.  Differential and interactive effects of calcium channel blockers and cholesterol content of the diet on jejunal uptake of lipids in rabbits.

Authors:  D A Hyson; A B Thomson; C T Kappagoda
Journal:  Lipids       Date:  1994-04       Impact factor: 1.880

8.  Inhibition of cholesteryl ester deposition in macrophages by calcium entry blockers: an effect dissociable from calcium entry blockade.

Authors:  A Daugherty; D L Rateri; G Schonfeld; B E Sobel
Journal:  Br J Pharmacol       Date:  1987-05       Impact factor: 8.739

9.  Inhibitory effect of clentiazem (TA-3090), a new calcium antagonist, on balloon catheter-induced intimal thickening of rabbit aorta.

Authors:  Y Saso; A Ohtani; A Odawara; H Iwasaki; K Takashima; T Morita
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

10.  International nifedipine trial on antiatherosclerotic therapy (INTACT).

Authors:  P R Lichtlen; U Nellessen; W Rafflenbeul; S Jost; H Hecker
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.